Microbiome-based therapies for Parkinson's disease

Area of Science:

• Neuroscience
• Microbiology
• Gastroenterology

Background:

• Gut microbiome dysbiosis is implicated in Parkinson's disease (PD) pathogenesis.
• The gut-brain axis mediates the bidirectional communication between the enteric nervous system (ENS) and central nervous system (CNS).

Purpose of the Study:

• To review mechanisms linking gut microbiota alterations to PD progression and motor control loss.
• To discuss the role of gut bacteria in PD pathophysiology, including inflammation and neurotransmitter imbalances.
• To explore emerging therapeutic strategies targeting the gut microbiome for PD.

Main Methods:

• Literature review synthesizing current evidence on gut microbiome's role in PD.
• Discussion of key factors: intestinal permeability, inflammation, oxidative stress, alpha-synuclein aggregation.
• Analysis of specific bacterial taxa, inflammatory markers (TNF-α, IL-1β, IL-6), and dietary interventions (Mediterranean, ketogenic diets).

Main Results:

• Gut microbiota composition and function significantly influence PD progression.
• Increased intestinal permeability, inflammation, and oxidative stress are key pathological factors.
• Gut bacteria impact dopamine production and levodopa metabolism, affecting motor control.

Conclusions:

• The gut microbiome is a critical factor in PD pathogenesis.
• Therapeutic strategies like probiotics, prebiotics, and dietary modifications show promise for PD management.
• Targeting the gut microbiome may lead to novel diagnostic tools and treatments for Parkinson's disease.